Zhongyuan Union Cell & Gene Engineering Corp Ltd Class A 600645
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 16.13
- Day Range
- CNY 16.04–16.50
- 52-Week Range
- CNY 12.88–21.77
- Bid/Ask
- CNY 16.32 / CNY 16.33
- Market Cap
- CNY 7.64 Bil
- Volume/Avg
- 4.3 Mil / 6.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 60.87
- Price/Sales
- 4.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,332
- Website
- http://www.vcanbio.com
Comparables
Valuation
|
Metric
|
600645
|
000504
|
4978
|
|---|---|---|---|
Price/Earnings (Normalized) | 60.87 | — | — |
Price/Book Value | 1.97 | 147.07 | 1.53 |
Price/Sales | 4.60 | 13.89 | 4.71 |
Price/Cash Flow | 27.04 | 36.53 | — |
Price/Earnings
600645
000504
4978
Financial Strength
|
Metric
|
600645
|
000504
|
4978
|
|---|---|---|---|
Quick Ratio | 1.46 | 0.92 | 11.63 |
Current Ratio | 1.72 | 0.95 | 12.43 |
Interest Coverage | 403.70 | −2.15 | — |
Quick Ratio
600645
000504
4978
Profitability
|
Metric
|
600645
|
000504
|
4978
|
|---|---|---|---|
Return on Assets (Normalized) | 2.46% | −5.78% | −0.30% |
Return on Equity (Normalized) | 3.63% | −261.47% | −0.32% |
Return on Invested Capital (Normalized) | 3.17% | −16.29% | −0.82% |
Return on Assets
600645
000504
4978
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fkjsrpyxx | Ktwrh | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pjpnqgvr | Vydfk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gbttzlxb | Cyskqy | $99.5 Bil | |
MRNA
| Moderna Inc | Qvbzngvm | Cml | $38.8 Bil | |
ARGX
| argenx SE ADR | Fftdqcpw | Szvd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rsrgzjmxs | Krq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sczhvldf | Dybysks | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qdrkhyby | Xdmlv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rttchrlfl | Mcykt | $12.5 Bil | |
INCY
| Incyte Corp | Nrwcmmrz | Ssbqvxz | $11.6 Bil |